Search results
Results From The WOW.Com Content Network
The Capsule Concierge™ kit provides instant access to small quantities of Capsugel® capsules in multiple sizes, polymers and applications with corresponding information to help guide the capsule selection process.
to Capsugel PCcaps® capsules designed for performing pre-clinical trials and to document their compliance with the definition for USP Enteric oral dosage form to qualify them for in vivo testing with rats. Test conditions: 50 rpm 37 °C USP
Counterfeit and diverted medicines are a growing threat to patients. Investment in former Capsugel site improves anti-counterfeiting security for Lonza’s global supply chain. Lonza customers are already benefiting from increased protection for their patients, well ahead of U.S. and EU legislation implementation.
Capsugel® offers integrated product development from feasibility assessments through clinical and specialized commercial manufacturing of finished dosage forms.
Visit Capsugel.com or contact your Capsugel representative at 800-845-6973. Capsugel will use reasonable efforts to include accurate and up-to-date information on this brochure but makes no warranties or representations of any kind as to its accuracy or completeness.
Building upon worldwide interest, Capsugel was pleased to organize this series of symposia for the pharmaceutical scientiļ¬c community. Product quality and performance is an important concern of regulatory authorities
Latest generation of Capsugel’s proprietary Fusion Sealing technology • High performance equipment with minimal waste of API and excipients • Capsule requires less sealant and delivers an enhanced seal
Samples of Capsugel Vcaps® Plus: Industrial production from Capsugel Colmar (France), Capsugel Puebla (Mexico) and Capsugel Sagamihara (Japan) plants. Dissolution testing: in vitro dissolution tests are performed with a blend: fill weight 400 mg. Composition: Caffeine / Lactose / Croscarmellose 25/65/10. Method: USP dissolution apparatus 2
manufacturing process and final dosage form. Capsugel’s oral multiparticulate technologies enable you to address a broad range of formulation needs. An assortment of manufacturing options can be tailored to the characteristics of the active compound(s) and target product profile. The drug-product intermediate
zero (Capsugel, France) were compressed with a platen up to 1.2 mm displacement, which corresponds to a reversible range of the strain. The testing speed was 0.2 mm/s. A line was fitted to a defined range of the profile as a secant from which the slope was taken as a stiffness modulus in N/mm. Consequently, the change of initial